Why Bind Therapeutics (BIND) Stock Is Down in Pre-Market Trading Today

NEW YORK (TheStreet) -- Bind Therapeutics  (BIND) plunged in pre-market trading on Thursday after the company announced it had ended its partnership with Amgen  (AMGN) to develop targeted cancer therapy.

Bind and Amgen signed a one-year collaboration agreement in January 2013 to produce cancer treatments using Bind's nanotechnology platform and an Amgen compound. The partnership ended because of unsatisfactory results from this collaboration.

"Despite achieving the objective of high tumor concentrations, the results were not sufficiently compelling to proceed forward and both collaborators have agreed that the program will not be continued," Bind's CEO Scott Minick said in a statement.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was down 11.88% to $11.35 at 9:15 a.m.

BIND Chart

BIND data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Bind Therapeutics (BIND) Strong On High Relative Volume Today

Bind Therapeutics (BIND) Weak On High Volume

5 Stocks Under $10 Set to Soar: Sportsman's Warehouse and More

Bind Therapeutics (BIND) Highlighted As Weak On High Volume